Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | PPIA | P62937 | 4/20 | 0.67 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840632 | 0.95 | ALDH1A1 (0.74) | ALDH1A1PPIAGPR27MEN1MAOA | |
| SCHEMBL15840711 | 0.89 | ALDH1A1 (0.74) | ALDH1A1PPIAGPR27MEN1KMT2A | |
| SCHEMBL25132396 | 0.89 | ALDH1A1 (0.74) | ALDH1A1PPIAGPR27MEN1KMT2A | |
| SCHEMBL15840705 | 0.86 | PPIA (0.78) | ALDH1A1PPIAGPR27MEN1KMT2A | |
| SCHEMBL15840630 | 0.86 | MAPT (0.68) | ALDH1A1PPIAGPR27MEN1KMT2A | |
| SCHEMBL11067896 | 0.84 | ALDH1A1 (0.78) | ALDH1A1MEN1MAOAMAOBKMT2A | |
| SCHEMBL15840648 | 0.83 | ALDH1A1 (0.62) | ALDH1A1PPIAGPR27LMNAMAPT | |
| SCHEMBL15840633 | 0.83 | ALDH1A1 (0.71) | ALDH1A1PPIAGPR27MEN1KMT2A | |
| SCHEMBL15840811 | 0.83 | MAPT (0.70) | ALDH1A1PPIAMEN1KMT2ALMNA | |
| SCHEMBL15840818 | 0.82 | PPIA (0.74) | ALDH1A1PPIAMEN1KMT2ACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885PPIA 1884/4885GPR27 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.